News
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...
Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...
France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...
GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct ...
Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...
In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results